MARK2 and early-onset autosomal dominant Alzheimer disease: In a 2013 study, Gu et al.[13] found that MARK2 enhances tau phosphorylation in vitro  and reported certain interactions between MARK2 and tau in the brain tissue of postmortem patients with Alzheimer's disease.